长江商报消息 ●长江商报记者 徐靓丽 作为湖北省生物医药龙头企业，九州通（600998.SH）正大力推进战略转型，转向轻资产运作，并成为 A股+公募REITs"双上市"公司。 公司产品管线也在持续扩充。6月5日，九州通发布公告称，公司"倍他米松磷酸钠注射液"获得药品注册 证书，该药品获批上市有利于扩大其市场份额，助力公司医药工业自产业务持续、稳健发展。 九州通近年来积极拓展医药工业自产及OEM业务，2024年医药工业自产业务实现销售收入30.07亿元， 同比增长21.49%。其中，京丰制药2024年营业收入达5.92亿元，同比增长26.92%。 公司盈利能力也获得较大提升，2025年一季度公司实现归母净利润约9.7亿元，同比大增80.38%。 在新医疗上，九州通与腾讯云等合作，开发了"九医诊所AI辅助诊断平台"，赋能万家诊所及基层医疗机 构，构建起包括诊前智能导诊、诊中辅助诊断、智能审方、诊后慢病管理等的全流程运营体系，并借助 AI智能化工具为医生、患者提供服务，大大提高诊疗效率、保障处方安全、提升患者就诊体验。截至 今年3月末，"九医诊所"会员店已达1377家。 在不动产证券化（REITs）战略方面，九州通 ...

Group 1 - Yara International's supervisor Peng Zhiyun is under investigation for insider trading, which is unrelated to the company's daily operations [2] - The company is operating normally despite the investigation, and Peng has applied to resign from his position [2] Group 2 - Fulin Precision's subsidiary Jiangxi Shenghua signed a supplementary agreement with CATL to increase production capacity to 160,000 tons/year in Jiangxi and 200,000 tons/year in Sichuan [3] - The agreement ensures that CATL will prioritize its demand from Jiangxi Shenghua and commit to purchasing at least 80% of the promised capacity annually [3] - This partnership is expected to enhance the competitiveness and sustainability of Fulin Precision's lithium iron phosphate business [3] Group 3 - Zai Jian Pharmaceutical signed an exclusive market promotion service agreement for recombinant human thyroid-stimulating hormone injection with Merck's Swiss subsidiary, Ares Trading S.A. [3] - The agreement includes a maximum authorization fee of RMB 250 million, with an initial payment of RMB 50 million due within 30 working days after the agreement takes effect [3] - The product is currently in the drug registration application stage [3] Group 4 - Wenta Technology announced that its major shareholder, Wuxi Guolian Integrated Circuit Investment Center, plans to reduce its stake by up to 3%, equating to 37.34 million shares [4] - The reduction will occur between June 27, 2025, and September 26, 2025 [4] Group 5 - Sanofi Guojian's application for a new drug listing for a recombinant anti-IL-1β humanized monoclonal antibody injection has been accepted by the National Medical Products Administration [5] - The drug is intended for the treatment of acute gouty arthritis and has achieved primary efficacy endpoints in Phase III clinical trials [5] Group 6 - Shuyou Shen's product STSP-0601 has been included in the priority review list by the National Medical Products Administration [6] - The product is a Class 1 therapeutic biological product approved for clinical trials for hemophilia A or B patients [7] Group 7 - Ningbo Port expects to complete a container throughput of 4.53 million TEUs in May, representing a year-on-year increase of 7.1% [8] - Wens Foodstuff's pig sales revenue increased by 14.23% year-on-year in May [8] - Dongfeng Motor's cumulative vehicle sales from January to May were 59,859 units, a decrease of 14.45% year-on-year [8]

双轨并行策略，加速新药上市进程 津药药业通过"创新线"与"仿制线" 双轨并行的策略持续强化研发实力，在近期药品审评中展现出强劲 动能。根据公开资料显示，公司注射用甲泼尼龙琥珀酸钠、乳酸钠林格注射液、氯化钾注射液等10个品 种共11个品规获得《药品补充申请批准通知书》，通过一致性评价，其中子公司津药和平为国内盐酸甲 氧氯普胺注射液通过一致性评价的首家企业；倍他米松磷酸钠注射液、间苯三酚注射液、吸入用乙酰半 胱氨酸溶液、吸入用复方异丙托溴铵溶液、盐酸溴己新注射液共5个品种获得《药品注册证书》，完善 了公司制剂产品群，产品矩阵不断扩充。 部分品种市场表现亮眼，前景广阔 津药药业是国内领先的甾体激素类药物生产企业之一，也是全球领先的氨基酸原料药制造商，其在2024 年度被认定为天津市先进智能工厂、企业重点实验室，彰显了其在行业内的领先地位与示范效应。 多元产品矩阵，覆盖广泛治疗领域 目前，公司主要产品丰富，拥有70余个原料药品种，包括地塞米松系列、泼尼松系列、甲泼尼龙系列、 倍他米松系列、氨基酸等，以及注射剂、软膏剂、乳膏剂、硬胶囊剂、丸剂、冻干粉针剂、吸入制剂、 片剂等10余个剂型药品，能够满足不同患者的治疗需求。 ...